Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early calcineurin inhibitor to everolimus conversion after de novo renal transplantation
2009-015918-22Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in kidney transplant (2 arms), sponsored by Novartis. Primary endpoints: Renal allograft function at Month 12 and Composite efficacy endpoint at Month 12. Started Mar 2010; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2009-015918-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015918-22.